| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24c714f929a56f57a3fe0bc0ec04b800 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2014-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_611557c132731b4e66d28720baa09882
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed00d3145291154f03876b52ca286cd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0958053b2b0503a39e109b829fbbc92a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa68eec69e09c730f7eac8cff770c8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d155cc6c2c70d5e3d33fb894d90182f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6be487f5db89c855c41e9c48866eaaff |
| publicationDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2683268-T3 |
| titleOfInvention |
Multispecific antibodies, multispecific activatable antibodies and methods for using them |
| abstract |
A multispecific activatable antibody that in an activated state binds to two or more targets or two or more epitopes or a combination thereof, the multispecific activatable antibody comprising: at least one antibody (AB1) that specifically binds to a first target or epitope, wherein AB1 comprises an IgG antibody comprising a heavy chain and a light chain; at least one scFv (AB2) that specifically binds to a second target or epitope, wherein an AB2 is fused to the amino terminus of each heavy chain of AB1; at least one first masking entity (MM1) coupled to AB1 that inhibits the binding of AB1 to its target when the multispecific activatable antibody is in an uncleaved state; at least a first cleavable entity (CM1) coupled to AB1, wherein CM1 is a polypeptide that functions as a substrate for a first protease, and where CM1 binds to MM1; at least one first masking entity (MM2) coupled to AB2 that inhibits the binding of AB2 to its target when the multispecific activatable antibody is in an uncleaved state; and at least a second cleavable moiety (CM2) coupled to AB2, in which CM2 is a polypeptide that functions as a substrate for a second protease, and in which CM2 is bound to MM2. |
| priorityDate |
2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |